REvascularization and Valve Intervention for Ischemic Valve diseasE: REVIVE Trial
REvascularization and Valve Intervention for Ischemic Valve diseasE: REVIVE Trial
Ischemic mitral regurgitation (MR) and coronary artery disease is common and associated with
 significant morbidity and mortality. Ischemic MR has been traditionally treated surgically
 through either valve repair or replacement at the time of concomitant bypass grafting.
 Although patients with ischemic MR represent a heterogeneous group, outcomes for these
 patients over the intermediate term is poor owing to left ventricle (LV) dysfunction causing
 MR and the presence of coronary disease, which portends poor survival. There is an emergence
 of percutaneous therapies to treat MR which have been shown to be a less invasive, safe, and
 viable approach to treat comorbid patients.

 The decision to treat ischemic MR either surgically or percutaneously is influenced by the
 presence of coronary disease and the ability to provide adequate revascularization. Mitral
 valve surgery concomitant to surgical revascularization, however, is associated with a
 several fold increase in mortality. In fact, the incremental risk increase is further
 magnified in high-risk patients. We therefore propose a novel prospective study to guide
 intervention for ischemic MR. Patients will be randomized to undergo surgical therapy with
 either mitral repair/replacement and/or concomitant coronary artery bypass grafting OR
 percutaneous mitral repair, followed by the ideal Heart Team determined mode of
 revascularization with either percutaneous coronary intervention or coronary artery bypass
 grafting.
Inclusion Criteria:

 1. Patients with severe ischemic Mitral regurgitation (MR), as defined by the 2017
 American Society of Echocardiography (ASE) guidelines for noninvasive evaluation of
 native valvular regurgitation.

 2. Presence of reversible myocardial ischemia confirmed by preoperative myocardial
 viability study using radionuclide imaging.

 Exclusion Criteria:

 1. Patients with mixed mitral valve pathology, including fibroelastic deficiency,
 rheumatic valve disease, ruptured mitral valve chordae, mitral valve endocarditis.

 2. Patients with acute ischemic MR, defined as MR caused by papillary muscle infarction
 and rupture.

 3. Age < 18 years.

 4. Prohibitive surgical risk or contraindications to Cardiopulmonary bypass (CPB) as
 defined by the Heart Team.

 5. Need for a concomitant surgical procedure, excluding Coronary artery bypass grafting
 (CABG), tricuspid valve repair, Patent foramen ovale (PFO) closure, Atrial septal
 defect (ASD) closure and Maze procedure.

 6. Prior mitral valve repair procedure (percutaneous or surgical).

 7. Leaflet anatomy unsuitable for MitraClip implantation, proper MitraClip positioning on
 the leaflets or sufficient reduction in MR by the MitraClip.